±èÅÂÇå
º´¸®°úÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ³¼Òº´¸®, ºñ´¢±â º´¸®, ÇǺκ´¸®
Á÷
ˤ
: ±³¼ö(º´¸®°úÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
7
ÇØ¿Ü
Down-regulation of claudin-2 in breast carcinomas is assocaited with advanced disease
6
ÇØ¿Ü
Clinicopathologic significance of cyclin A, p27 and Skp2 in ovarian epithelial tumors
5
ÇØ¿Ü
Proteomic Identification of Overexpressed PRDX 1 and Its Clinical Implications in Ovarian Carcinoma
4
ÇØ¿Ü
Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI Proteins u=in human ovarian cancer cells
3
ÇØ¿Ü
Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance on ovarian epithelial tumours.
2
ÇØ¿Ü
Absence of a FOXL3 mutation(402C->G) in the blood of adult type granulosa cell tumor in patients prossessing the FOXL3 mutation
1
ÇØ¿Ü
A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53.
1
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729